Business Wire | Aug 12, 2020 04:01PM EDT

Personalis to Participate at the Needham Virtual Cancer Diagnostics 1x1 Conference

Aug. 12, 2020

MENLO PARK, Calif.--(BUSINESS WIRE)--Aug. 12, 2020--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that company management will participate in the 1-on-1 meetings at the upcoming Needham Virtual Cancer Diagnostics 1x1 Conference on Tuesday, August 18, 2020.

About Personalis, Inc.

Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient's cancer and immune response. The Personalis(r) ImmunoID NeXT Platform(r) is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. Personalis also provides genomic information to the VA Million Veterans Program as part of their goal to sequence over a million veteran genomes. The Personalis Clinical Laboratory is GxP aligned as well as CLIA'88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc).

View source version on businesswire.com: https://www.businesswire.com/news/home/20200812005619/en/

CONTACT: Investor Relations Contact: Caroline Corner investors@personalis.com 415-202-5678

CONTACT: Media Contact: Jennifer Havlek pr@personalis.com www.personalis.com 650-752-1300